Cheng Li
Good morning, and good evening to our global investors. Thank you for joining InnoCare Pharma 2026 Interim Results. This is [ Li Chen Feng ] from China Healthcare from Goldman Sachs. With us today is InnoCare’s management team, including Dr. Jasmine Cui, the Chairlady and CEO; Dr. Xiangyang Chen, the CTO; Mr. Xin Fu, CFO; Dr. Renbin Zhao, Senior VP of Clinical Development; Dr. Carrie Zhou, VP of Medical Research; Dr. Jason Zhang, VP of Translational Research; and Ms. Bonnie Yuan, Senior Director of IR.
Before we kick off the session, I would like to highlight that this call is strictly for clients of Goldman Sachs and InnoCare only, and this conversation is not intended for the media and is off the record. Participants will be removed from the call if they cannot be properly identified. And this call is not for the purpose of sharing or receiving nonpublic or otherwise confidential information. Attendees are public side market participants who may not receive and should not request nonpublic or otherwise confidential information about issuers or securities or about the market securities.
InnoCare just put out the results a couple of hours ago. And today, we’re going to have the management team to discuss the business updates and first half results. After the prepared remarks, you do get a chance to ask questions. [Operator Instructions] Now without further ado, I’m going to turn the call to the management team to get started.
Credit: Source link
